Small Extracellular Vesicle (sEV) uptake from lung adenocarcinoma and squamous cell carcinoma alters T-cell cytokine expression and modulates protein profiles in sEV biogenesis

Background: Despite advances in immunotherapy, non-small-cell lung carcinoma (NSCLC)’s clinical success is limited, possibly due to substantial immunological alterations in advanced cancer patients. This study examines the immunomodulatory effects of sEVs derived from lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC) on T cells. Methods: SEVs were isolated from lung cancer cell lines and Jurkat-E6.1. SEV size and morphology were analyzed by NTA and TEM, respectively, while Western blotting confirmed sEV markers. SEV uptake was assessed, followed by resazurin assay, RNA isolation, quantification, cDNA preparation, RT-PCR, nano LC-MS, and bioinformatic analysis, before and after treating Jurkat-E6.1 cells with sEVs from A549 and SKMES1. Results: Cancer-derived sEVs were efficiently internalized by immune cells, reducing T-cell viability. The real-time PCR analysis showed downregulation of KI67, BCL2, BAX, TNFA, IL6, TGFβ, and IL10, suggesting reduced proliferation, dysregulated apoptosis, and impaired inflammatory and immunosuppressive signaling, and the upregulation of GZMB and IL2 suggests retained cytotoxic potential but possibly dysfunctional T-cell activation. Proteomic analysis revealed 39 differentially abundant proteins (DAPs) in ADC-treated T cells and 276 in SCC-treated T cells, with 19 shared DAPs. Gene Ontology (GO) analysis of these DAPs highlighted processes such as sEV biogenesis, metabolic pathways, and regulatory functions, with ADC sEVs influencing NAD metabolism, ECM binding, and oxidoreductase activity, while SCC sEVs affected mRNA stability, amino acid metabolism, and cadherin binding. The cytoplasmic colocalization suggests the presence of these proteins in the cellular and extracellular lumen, indicating the potential of further release of these proteins in the vesicles by T cells. Conclusion: Lung cancer-derived sEVs regulate T-cell activities through immunoregulatory signaling. The molecular interactions between sEVs and immune cells can reveal novel tumor immune regulatory mechanisms and therapeutic targets.

1. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33.
https://doi.org/10.3322/CAAC.21654.
2. Oser, M.G.; Niederst, M.J.; Sequist, L.V.; Engelman, J.A. Transformation from Non-Small-Cell Lung Cancer to Small-Cell Lung
Cancer: Molecular Drivers and Cells of Origin. Lancet Oncol. 2015, 16, e165–e172. https://doi.org/10.1016/S1470-2045(14)71180-5.
3. Padinharayil, H.; Varghese, J.; John, M.C.; Rajanikant, G.K.; Wilson, C.M.; Al-Yozbaki, M.; Renu, K.; Dewanjee, S.; Sanyal, R.;
Dey, A.; et al. Non-Small Cell Lung Carcinoma (NSCLC): Implications on Molecular Pathology and Advances in Early
Diagnostics and Therapeutics. Genes Dis. 2023, 10, 960–989. https://doi.org/10.1016/J.GENDIS.2022.07.023.
4. Brinton, L.T.; Sloane, H.S.; Kester, M.; Kelly, K.A. Formation and Role of Exosomes in Cancer. Cell. Mol. Life Sci. 2015, 72, 659–
671. https://doi.org/10.1007/s00018-014-1764-3.
5. Zebrowska, A.; Widlak, P.; Whiteside, T.; Pietrowska, M. Signaling of Tumor-Derived Sev Impacts Melanoma Progression. Int.
J. Mol. Sci. 2020, 21, 5066. https://doi.org/10.3390/ijms21145066.
6. Zebrowska, A.; Skowronek, A.; Wojakowska, A.; Widlak, P.; Pietrowska, M. Metabolome of Exosomes: Focus on Vesicles
Released by Cancer Cells and Present in Human Body Fluids. Int. J. Mol. Sci. 2019, 20, 3461. https://doi.org/10.3390/ijms20143461.
7. Padinharayil, H.; George, A. Small Extracellular Vesicles: Multi-Functional Aspects in Non-Small Cell Lung Carcinoma. Crit.
Rev. Oncol. Hematol. 2024, 198, 104341. https://doi.org/10.1016/j.critrevonc.2024.104341.
8. Padinharayil, H.; Varghese, J.; Wilson, C.; George, A. Mesenchymal Stem Cell-Derived Exosomes: Characteristics and
Applications in Disease Pathology and Management. Life Sci. 2024, 342, 122542. https://doi.org/10.1016/j.lfs.2024.122542.
9. Welsh, J.A.; Goberdhan, D.C.I.; O’Driscoll, L.; Buzas, E.I.; Blenkiron, C.; Bussolati, B.; Cai, H.; Di Vizio, D.; Driedonks, T.A.P.;
Erdbrügger, U.; et al. Minimal Information for Studies of Extracellular Vesicles (MISEV2023): From Basic to Advanced
Approaches. J. Extracell. Vesicles 2024, 13, e12404. https://doi.org/10.1002/JEV2.12404.
10. Whiteside, T.L. Tumor-Derived Exosomes and Their Role in Cancer Progression. Adv. Clin. Chem. 2016, 74, 103–141.
https://doi.org/10.1016/bs.acc.2015.12.005.
11. Kok, V.C.; Yu, C.C. Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development. Int. J. Nanomed. 2020,
15, 8019–8036. https://doi.org/10.2147/IJN.S272378.
12. Théry, C.; Zitvogel, L.; Amigorena, S. Exosomes: Composition, Biogenesis and Function. Nat. Rev. Immunol. 2002, 2, 569–579.
https://doi.org/10.1038/nri855.
13. Ma, F.; Vayalil, J.; Lee, G.; Wang, Y.; Peng, G. Emerging Role of Tumor-Derived Extracellular Vesicles in T Cell Suppression and
Dysfunction in the Tumor Microenvironment. J. Immunother. Cancer 2021, 9, e003217. https://doi.org/10.1136/JITC-2021-003217.
14. Whiteside, T.L. The Effect of Tumor-Derived Exosomes on Immune Regulation and Cancer Immunotherapy. Future Oncol. 2017,
13, 2583–2592. https://doi.org/10.2217/fon-2017-0343.
15. Azambuja, J.H.; Ludwig, N.; Yerneni, S.S.; Braganhol, E.; Whiteside, T.L. Arginase-1+ Exosomes from Reprogrammed
Macrophages Promote Glioblastoma Progression. Int. J. Mol. Sci. 2020, 21, 3990. https://doi.org/10.3390/ijms21113990.
Proteomes 2025, 13, 15 21 of 22
16. Zhao, Y.; Liu, L.; Sun, R.; Cui, G.; Guo, S.; Han, S.; Li, Z.; Bai, T.; Teng, L. Exosomes in Cancer Immunoediting and
Immunotherapy. Asian J. Pharm. Sci. 2022, 17, 193–205. https://doi.org/10.1016/J.AJPS.2021.12.001.
17. Soltész, B.; Buglyó, G.; Németh, N.; Szilágyi, M.; Pös, O.; Szemes, T.; Balogh, I.; Nagy, B. The Role of Exosomes in Cancer
Progression. Int. J. Mol. Sci. 2021, 23, 8. https://doi.org/10.3390/IJMS23010008.
18. Whiteside, T.L.; Mandapathil, M.; Szczepanski, M.; Szajnik, M. Mechanisms of Tumor Escape from the Immune System:
Adenosine-Producing Treg, Exosomes and Tumor-Associated TLRs. Bull. Cancer 2011, 98, E25–E31.
https://doi.org/10.1684/bdc.2010.1294.
19. Whiteside, T.L. Immune Suppression in Cancer: Effects on Immune Cells, Mechanisms and Future Therapeutic Intervention.
Semin. Cancer Biol. 2006, 16, 3–15. https://doi.org/10.1016/j.semcancer.2005.07.008.
20. Jeong, W.K.; Wieckowski, E.; Taylor, D.D.; Reichert, T.E.; Watkins, S.; Whiteside, T.L. Fas Ligand-Positive Membranous Vesicles
Isolated from Sera of Patients with Oral Cancer Induce Apoptosis of Activated T Lymphocytes. Clin. Cancer Res. 2005, 11, 1010–
1020. https://doi.org/10.1158/1078-0432.1010.11.3.
21. Zhou, Q.; Wei, S.; Wang, H.; Li, Y.; Fan, S.; Cao, Y.; Wang, C. T Cell-Derived Exosomes in Tumor Immune Modulation and
Immunotherapy. Front. Immunol. 2023, 14, 1130033. https://doi.org/10.3389/FIMMU.2023.1130033.
22. Taylor, D.D.; Gerçel-Taylor, C. Tumour-Derived Exosomes and Their Role in Cancer-Associated T-Cell Signalling Defects. Br.
J. Cancer 2005, 92, 305–311. https://doi.org/10.1038/sj.bjc.6602316.
23. Clayton, A.; Mitchell, J.P.; Court, J.; Mason, M.D.; Tabi, Z. Human Tumor-Derived Exosomes Selectively Impair Lymphocyte
Responses to Interleukin-2. Cancer Res. 2007, 67, 7458–7466.
24. Baitsch, L.; Baumgaertner, P.; Devêvre, E.; Raghav, S.K.; Legat, A.; Barba, L.; Wieckowski, S.; Bouzourene, H.; Deplancke, B.;
Romero, P.; et al. Exhaustion of Tumor-Specific CD8+ T Cells in Metastases from Melanoma Patients. J. Clin. Investig. 2011, 121,
2350–2360. https://doi.org/10.1172/JCI46102.
25. Wherry, E.J. T Cell Exhaustion. Nat. Immunol. 2011, 12, 492–499. https://doi.org/10.1038/ni.2035.
26. Owen, D.L.; Sjaastad, L.E.; Farrar, M.A. Regulatory T Cell Development in the Thymus. J. Immunol. 2019, 203, 2031–2041.
https://doi.org/10.4049/jimmunol.1900662.
27. Ye, S.B.; Li, Z.L.; Luo, D.H.; Huang, B.J.; Chen, Y.S.; Zhang, X.S.; Cui, J.; Zeng, Y.X.; Li, J. Tumor-Derived Exosomes Promote
Tumor Progression and T-Cell Dysfunction through the Regulation of Enriched Exosomal MicroRNAs in Human
Nasopharyngeal Carcinoma. Oncotarget 2014, 5, 5439–5452. https://doi.org/10.18632/oncotarget.2118.
28. Wieckowski, E.U.; Visus, C.; Szajnik, M.; Szczepanski, M.J.; Storkus, W.J.; Whiteside, T.L. Tumor-Derived Microvesicles
Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes. J. Immunol.
2009, 183, 3720–3730. https://doi.org/10.4049/jimmunol.0900970.
29. Salakou, S.; Tsamandas, A.C.; Bonikos, D.S.; Papapetropoulos, T.; Dougenis, D. The Potential Role of Bcl-2, Bax, and Ki67
Expression in Thymus of Patients with Myasthenia Gravis, and Their Correlation with Clinicopathologic Parameters. Eur. J.
Cardio-Thorac. Surg. 2001, 20, 712–721. https://doi.org/10.1016/S1010-7940(01)00776-X.
30. Evans, H.G.; Roostalu, U.; Walter, G.J.; Gullick, N.J.; Frederiksen, K.S.; Roberts, C.A.; Sumner, J.; Baeten, D.L.; Gerwien, J.G.;
Cope, A.P.; et al. TNF-α Blockade Induces IL-10 Expression in Human CD4+ T Cells. Nat. Commun. 2014, 5, 3199.
https://doi.org/10.1038/ncomms4199.
31. Jutel, M.; Akdis, M.; Budak, F.; Aebischer-Casaulta, C.; Wrzyszcz, M.; Blaser, K.; Akdis, C.A. IL-10 and TGF-β Cooperate in the
Regulatory T Cell Response to Mucosal Allergens in Normal Immunity and Specific Immunotherapy. Eur. J. Immunol. 2003, 33,
1205–1214. https://doi.org/10.1002/EJI.200322919.
32. Akbar, A.N.; Borthwick, N.J.; Wickremasinghe, R.G.; Panayiotidis, P.; Pilling, D.; Bofill, M.; Krajewski, S.; Reed, J.C.; Salmon,
M. Interleukin-2 Receptor Common Gamma-Chain Signaling Cytokines Regulate Activated T Cell Apoptosis in Response to
Growth Factor Withdrawal: Selective Induction of Anti-Apoptotic (Bcl-2, Bcl-XL) but Not pro-Apoptotic (Bax, Bcl-XS) Gene
Expression. Eur. J. Immunol. 1996, 26, 294–299. https://doi.org/10.1002/EJI.1830260204.
33. Hay, Z.L.Z.; Slansky, J.E. Granzymes: The Molecular Executors of Immune-Mediated Cytotoxicity. Int. J. Mol. Sci. 2022, 23, 1833.
https://doi.org/10.3390/IJMS23031833.
Proteomes 2025, 13, 15 22 of 22
34. Po, A.; Eyers, C.E. Top-Down Proteomics and the Challenges of True Proteoform Characterization. J. Proteome Res. 2023, 22,
3663–3675. https://doi.org/10.1021/ACS.JPROTEOME.3C00416.
35. Schaffer, L.V.; Millikin, R.J.; Shortreed, M.R.; Scalf, M.; Smith, L.M. Improving Proteoform Identifications in Complex Systems
Through Integration of Bottom-Up and Top-Down Data. J. Proteome Res. 2020, 19, 3510.
https://doi.org/10.1021/ACS.JPROTEOME.0C00332.